Dimerix Limited and controlled entity Half-year report

Dimerix Limited (ASX: $DXB) reported a loss of $6,673,057 for the half-year ended 31 December 2023. The loss for the Group was attributed to research and development expenditure of $5,076,663 and corporate and administration expenses of $1,783,259. During this period, the Group continued to focus on the development of Dimerix' DMX-200 drug candidate in Focal Segmental Glomerulosclerosis (FSGS). The company also made progress with its DMX-700 drug candidate, which has shown promising results in the treatment of Chronic Obstructive Pulmonary Disease (COPD).

Executive Commentary

Our goal is to develop patient-friendly products that treat unmet medical needs in important therapeutic areas. We are committed to integrating Environmental, Social and Governance (ESG) considerations across the development cycle of our informed programs, processes, and decision making. The DMX-200 program, aimed at treating FSGS, has shown encouraging results, and we have commenced a pivotal Phase 3 clinical study. Additionally, the DMX-700 program targeting COPD has demonstrated positive outcomes in pre-clinical studies. We are optimistic about the potential of these programs to address critical unmet medical needs.

Summary of Financial Report

Dimerix Limited (ASX: $DXB) reported a loss of $6,673,057 for the half-year ended 31 December 2023, primarily attributed to research and development expenditure. The company continued to focus on the development of the DMX-200 drug candidate for FSGS and made progress with the DMX-700 drug candidate for COPD. Dimerix aims to develop patient-friendly products targeting multiple global territories, with a focus on the United States, European, and Asian markets. The company's commitment to integrating ESG considerations across its programs and processes demonstrates a values-led culture. With ongoing efforts in research and development, Dimerix remains optimistic about the potential of its drug candidates to address critical unmet medical needs.